Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 95Recurrence 11Neoplasms, Plasma Cell 9Immunoglobulin Light-chain Amyloidosis 6Neoplasms 5Smoldering Multiple Myeloma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmacytoma 2Neoplasm, Residual 2Lymphoma 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Renal Insufficiency 1Prostatic Neoplasms 1Plasmablastic Lymphoma 1Paraproteinemias 1Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1Myelodysplastic Syndromes 1Microsatellite Unstable Colorectal Cancer 1Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hypergammaglobulinemia 1Disease 1Chromosome 17 deletion 1

Interventions

Cyclophosphamide 17Etoposide 10fludarabine 9Whole-Body Irradiation 9Brentuximab Vedotin 9Melphalan 8fludarabine phosphate 7Vincristine 7Mycophenolic Acid 7Gemcitabine 7Doxorubicin 7Prednisone 6Granulocyte Colony-Stimulating Factor 6Busulfan 6Vorinostat 5Rituximab 5Peripheral Blood Stem Cell Transplantation 5Lenalidomide 5Filgrastim 5Cytarabine 5Bortezomib 5romidepsin 4pembrolizumab 4duvelisib 4Tacrolimus 4Stem Cell Transplantation 4Carmustine 4etoposide phosphate 3Sirolimus 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell × daratumumab × Clear all
NCT04251065 2025-03-28

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Fondazione Italiana Linfomi - ETS

Phase 2 Terminated
8 enrolled 17 charts
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡